全体要約
地域別では、アジア太平洋地域が最も急成長している市場であり、製薬業界の成長や政府の支援政策が寄与しています。北米は市場の最大シェアを持ち、バイオシミラーや生物製剤市場の急成長が影響しています。市場にはIQVIA、LabCorp、Charles River Laboratories、WuXi AppTecなどの主要企業が存在します。
関連する質問
520億ドル（2026年）
6.1%（2021年から2026年）
IQVIA, LabCorp, Charles River Laboratories, WuXi AppTec, Syneos Health, Parexel International, PPD, ICON Plc, Medpace Holdings, SGS, PSI CRO AG, Axcent Advanced Analytics, BIO Agile Therapeutics, Firma Clinical Research, Acculab Life Sciences, Azelix, CTserv, Pepgra, Dove Quality Solutions, Novotech Health Holding, Geneticist Inc., Linical Americas, Frontage Holding Corporation, Celerion
臨床試験の数の増加, 孤児病・希少疾患の増加, 自社開発の高コスト
概要
サービスの種類別では、臨床試験市場においてラボサービスセグメントが最大のシェアを占めました。
サービスタイプに基づいて、臨床試験市場はプロトコル設計、サイト特定、患者募集、ラボサービス、バイオアナリティカルテスト、分析テスト、臨床試験供給および物流サービス、分散臨床サービス、臨床試験データ管理サービス、医療機器テストサービス、その他のサービスに分かれています。ラボサービスは臨床試験サービス市場のリーディングセグメントであり、これは臨床研究の専門家がそのようなサービスをアウトソースすることを選好する傾向の高まりに起因しています。
アジア太平洋：臨床試験市場で最も成長が早い地域です。
アジア太平洋市場は予測期間中に最も高いCAGRで成長することが予測されています。この地域の高い成長率は、急成長している製薬産業、好意的な政府の政策、製薬会社がこの地域に製造施設を設立する数の増加、さらにはこの地域での臨床試験のコストが低いことに起因しています。
北アメリカ：北アメリカ地域は臨床試験市場で最大のシェアを占めています。
北米は臨床試験市場で最大のシェアを占めています。バイオシミラーおよびバイオロジクス市場の急成長と臨床試験活動の増加は、市場成長を促進する主な要因です。
プライマリの内訳
この調査には、部品供給者からTier 1企業、OEMまでのさまざまな業界専門家からの見識が含まれています。プライマリーの内訳は以下の通りです：
回答者別 - 供給側 - 40%、需要側 - 60%
役職別 - エグゼクティブ - 25%、CXO及びディレクター - 30%、マネージャー - 45%
地域別 - 北米 - 40%、ヨーロッパ - 25%、アジア太平洋 - 20%、ラテンアメリカ - 10%、中東・アフリカ - 5%
臨床試験市場は、IQVIA（米国）、LabCorp（米国）、チャールズリバーラボラトリーズ（米国）、WuXi AppTec（中国）、Syneos Health（米国）、Parexel International（米国）、PPD（米国）、ICON Plc（米国）など、数社のグローバルな確立企業によって支配されています。市場で活動している他の企業には、Medpace Holdings（米国）、SGS（スイス）、PSI CRO AG（米国）、Axcent Advanced Analytics（米国）、BIO Agile Therapeutics（米国）、Firma Clinical Research（米国）、Acculab Life Sciences（米国）、Azelix（米国）、CTserv（米国）、Pepgra（英国）、Dove Quality Solutions（米国）、Novotech Health Holding（オーストラリア）、Geneticist Inc.（米国）、Linical Americas（米国）、Frontage Holding Corporation（米国）、Celerion（米国）が含まれています。
研究対象：
レポートは臨床試験市場を地域（北アメリカ、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東およびアフリカ）、段階（フェーズI、フェーズII、フェーズIII、フェーズIV）、サービスタイプ（プロトコル設計、サイト特定、患者募集、ラボサービス、バイオアナリティカル試験サービス（細胞ベースのアッセイ、ウイルス学試験、方法開発、最適化および検証、血清学、免疫原性および中和抗体、バイオマーカー試験サービス、PK/PD試験サービス、その他のバイオアナリティカル試験サービス）、分析試験サービス、臨床試験供給および物流サービス、分散型臨床サービス、臨床試験データ管理サービス、医療機器試験サービス、その他の臨床試験サービス）、治療領域（腫瘍学、感染症、心臓病学、神経学、女性の健康、遺伝病、免疫学、およびその他の治療領域）、アプリケーション（ワクチン、細胞および遺伝子治療、小分子、その他のアプリケーション）に基づいてセグメント化しています。
この報告書は、臨床試験市場における市場の推進要因、課題、および機会の包括的なレビューも提供。
レポート購入の主なメリット：
この報告書は、市場のリーダーや新規参入者が全体市場およびサブセグメントの収益数値の最も近い推定値に関する情報を得るのに役立ちます。この報告書は、ステークホルダーが競争環境を理解し、ビジネスをより適切にポジショニングし、適切な市場進出戦略を計画するための洞察を得るのに役立ちます。また、この報告書は、ステークホルダーが臨床試験市場の動向を理解し、市場の主要なドライバー、課題、および機会に関する情報を提供します。
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 イントロダクション 40
1.1 調査の目的 40
1.2 市場の定義 40
1.2.1 包含・除外事項 40
1.3 市場範囲 41
1.3.1 調査対象年 42
1.4 通貨 42
1.5 制約 42
1.6 ステークホルダー 43
1.7 変化のサマリー 43
2 調査手法 44
2.1 リサーチデータ 44
2.1.1 二次データ 45
2.1.2 一次データ 46
2.2 市場規模予測 47
2.3 成長率の前提・予測 50
2.4 市場の内訳とデータのトライアンギュレーション 53
2.5 プライマリーからの洞察 54
2.6 調査の前提 54
2.6.1 Covid-19固有の前提 55
2.7 リスク分析 55
3 エグゼクティブサマリー 56
4 更なる考察 60
4.1 臨床試験市場の概要 60
4.2 北米の臨床試験市場シェア（フェーズ別・国別）（2020年 61
4.3 臨床試験市場、バイオ分析サービスタイプ別
5 市場概要 63
5.1 イントロダクション 63
5.2 市場力学 63
5.2.1 促進要因 64
- 5.2.1.1 医薬品研究開発への投資拡大 64
- 5.2.1.2 増加する臨床試験 66
- 5.2.1.3 自社での医薬品開発コストが高い 66
- 5.2.1.4 希少疾病の普及が進む 67
5.2.2 市場機会 68
5.2.3 課題 70
- 5.2.3.1 臨床試験に携わる熟練した専門家の不足 70
- 5.2.3.2 革新的な医薬品分子に対する独自の分析試験アプローチの必要性 70
5.2.4 市場動向 71
- 5.2.4.1 人工知能を用いた創薬ツールの採用について 71
- 5.2.4.2 アジア新興国でのアウトソーシング活動の活発化 71
- 5.2.4.3 エンドツーエンドの研究開発サービス統合ソリューション 73
5.3 レンジ/シナリオ 73
5.4 COVID-19が臨床試験市場に与える影響について 74
5.5 ポーターのファイブフォース分析 75
5.5.1 新規参入の脅威 75
5.5.2 代替品の脅威 75
5.5.3 買い手の交渉力 75
5.5.4 サプライヤーの交渉力 76
5.5.5 競争の激しさ 76
5.6 顧客ビジネスにインパクトを与えるトレンドやディスラプション 76
5.7 エコシステム分析 77
5.8 規制分析 79
6 臨床試験の市場、フェーズ別 82
6.1 イントロダクション 83
6.2 臨床試験企画・立案ソリューション 84
6.3 フェーズI 87
6.4 フェーズII 89
6.5 フェーズIII 92
6.6 フェーズIV 94
7 臨床試験の市場、サービスタイプ別 97
7.1 イントロダクション 98
7.2 プロトコル設計 99
7.3 サイトの識別 101
7.4 患者募集 103
7.5 ラボラトリーサービス 105
7.6 バイオ分析試験サービス 109
7.7 臨床試験データマネジメントサービス 124
7.7.1 データマネジメント・サービス部門は、次のように予測
7.8 臨床試験サプライ＆ロジスティックサービス 127
7.9 臨床試験サービスの分散化 128
7.10 医療機器試験サービス 130
7.11 その他の臨床試験サービス 132
8 臨床試験の市場、治療エリア別 135
8.1 イントロダクション 136
8.2 オンコロジー 136
8.2.1 がん罹患率の上昇が市場成長を促進 136
8.3 感染症 140
8.4 神経学 142
8.5 免疫学 145
8.6 循環器内科 147
8.7 遺伝性疾患 149
8.8 ウィメンズヘルス 151
8.9 その他の治療分野 153
9 臨床試験の市場、用途別 156
9.1 イントロダクション 157
9.2 低分子化合物 157
9.3 ワクチン 160
9.4 細胞・遺伝子治療 162
9.5 その他の用途 166
10 臨床試験の市場、地域別 168
10.1 イントロダクション 169
10.2 北米 169
10.2.1 米国 173
10.2.2 カナダ 176
10.3 ヨーロッパ 179
10.3.1 ドイツ 182
10.3.2 英国 185
10.3.3 フランス 188
10.3.4 イタリア 191
10.3.5 スペイン 194
- 10.3.5.1 研究開発費の増加が臨床試験の市場成長を後押し
10.3.6 欧州以外の地域（卵） 198
10.4 アジア太平洋 (APAC) 201
10.4.1 中国 205
10.4.2 日本 208
10.4.3 インド 211
10.4.4 その他アジア太平洋 214
10.5 ラテンアメリカ 217
10.6 中東・アフリカ 220
11 競合情勢 224
11.1 イントロダクション 224
11.2 主要プレーヤーが採用するRight-to-Winアプローチ 224
11.3 市場シェア分析 226
11.4 企業評価４象限分類 228
11.4.1 STARS 228
11.4.2 EMERGING LEADERS 228
11.4.3 PERVASIVE PLAYERS 228
11.4.4 PARTICIPANTS 228
11.5 競合ベンチマーキング 230
11.5.1 カンパニー・サービス・フットプリント（20社） 230
11.5.2 会社の地域フットプリント（20社） 231
11.6 COMPETITIVE SCENARIO AND TRENDS 232
11.6.1 サービスローンチ 232
11.6.2 ディール 233
11.6.3 その他の展開 234
12 企業プロファイル 235
12.1 主要企業 235
12.1.1 IQVIA 235
12.1.2 LABCORP DRUG DEVELOPMENT (COVANCE) 240
12.1.3 SYNEOS HEALTH INC. 246
12.1.4 WUXI APPTEC 252
12.1.5 CHARLES RIVER LABORATORIES 259
12.1.6 PAREXEL INTERNATIONAL 265
12.1.7 PRA HEALTH SCIENCES 271
12.1.8 PPD INC 275
12.1.9 ICON PLC 281
12.1.10 MEDPACE HOLDINGS INC 287
12.1.11 ACM GLOBAL LABORATORIES 289
12.1.12 ADVANCED CLINICAL 291
12.1.13 SGS 293
12.1.14 FRONTAGE HOLDINGS CORPORATION 296
12.1.15 PSI CRO AG 300
12.1.16 BIO AGILE THERAPEUTICS 301
12.2 他の有力企業 303
12.2.1 AZELIX 303
12.2.2 CTSERV 304
12.2.3 PEPGRA 304
12.2.4 AXCENT ADVANCED ANALYTICS (A3) 305
12.2.5 DOVE QUALITY SOLUTIONS 306
12.2.6 FIRMA CLINICAL RESEARCH 306
12.2.7 CELERION 307
12.2.8 NOVOTECH HEALTH HOLDINGS 308
12.2.9 GENETICIST INC. 308
12.2.10 LINICAL AMERICAS 309
13 付録 310
13.1 ディスカッションガイド 310
13.2 ナレッジストア : MarketAndMarketのサブスクリプションポータル 313
13.3 可能なカスタマイズ 315
13.4 関連レポート 316
13.5 執筆者の詳細 317
2017 vs. 2019 208
2021 VS. 2026（十億米ドル） 62
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
Table of Contents
1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.2.1 INCLUSIONS & EXCLUSIONS 40
1.3 MARKET SCOPE 41
1.3.1 YEARS CONSIDERED FOR THE STUDY 42
1.4 CURRENCY 42
1.5 LIMITATIONS 42
1.6 STAKEHOLDERS 43
1.7 SUMMARY OF CHANGES 43
2 RESEARCH METHODOLOGY 44
2.1 RESEARCH DATA 44
2.1.1 SECONDARY DATA 45
2.1.2 PRIMARY DATA 46
2.2 MARKET SIZE ESTIMATION 47
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 50
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 53
2.5 INSIGHTS FROM PRIMARIES 54
2.6 RESEARCH ASSUMPTIONS 54
2.6.1 COVID-19 SPECIFIC ASSUMPTIONS 55
2.7 RISK ANALYSIS 55
3 EXECUTIVE SUMMARY 56
4 PREMIUM INSIGHTS 60
4.1 CLINICAL TRIALS MARKET OVERVIEW 60
4.2 NORTH AMERICA: CLINICAL TRIALS MARKET SHARE, BY PHASE & COUNTRY (2020) 61
4.3 CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICE TYPE
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 63
5.2.1 DRIVERS 64
- 5.2.1.1 Increasing investment in pharmaceutical R&D 64
- 5.2.1.2 Increasing number of clinical trials 66
- 5.2.1.3 High cost of in-house drug development 66
- 5.2.1.4 Rising prevalence of orphan and rare diseases 67
5.2.2 OPPORTUNITIES 68
- 5.2.2.1 Growth in drugs and biologics market despite COVID-19 pandemic 68
- 5.2.2.2 Rising demand for specialized testing services among end users 69
- 5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies 70
5.2.3 CHALLENGES 70
- 5.2.3.1 Shortage of skilled professionals for clinical trials 70
- 5.2.3.2 Requirement of unique analytical testing approaches for innovative drug molecules 70
5.2.4 MARKET TRENDS 71
- 5.2.4.1 Adoption of artificial intelligence-based tools for drug discovery 71
- 5.2.4.2 Increasing outsourcing activities in emerging Asian economies 71
- 5.2.4.3 Integrated end-to-end R&D service solutions 73
5.3 RANGES/SCENARIOS 73
5.4 IMPACT OF COVID-19 ON CLINICAL TRIALS MARKET 74
5.5 PORTER’S FIVE FORCES ANALYSIS 75
5.5.1 THREAT OF NEW ENTRANTS 75
5.5.2 THREAT OF SUBSTITUTES 75
5.5.3 BARGAINING POWER OF BUYERS 75
5.5.4 BARGAINING POWER OF SUPPLIERS 76
5.5.5 DEGREE OF COMPETITION 76
5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 76
5.7 ECOSYSTEM ANALYSIS 77
5.8 REGULATORY ANALYSIS 79
6 CLINICAL TRIALS MARKET, BY PHASE 82
6.1 INTRODUCTION 83
6.2 CLINICAL TRIALS PLANNING AND DESIGNING SOLUTION 84
6.3 PHASE I 87
6.3.1 ROBUST PIPELINE OF PHARMACEUTICAL COMPANIES DRIVES THE GROWTH OF THIS SEGMENT 87
6.4 PHASE II 89
6.4.1 LONG DURATION OF PHASE II STUDIES PROVIDES GROWTH OPPORTUNITIES FOR CROS 89
6.5 PHASE III 92
6.5.1 RISING COSTS OF PHASE III TRIALS INCREASES THE DEMAND FOR COST-EFFECTIVE CLINICAL RESEARCH SERVICES 92
6.6 PHASE IV 94
6.6.1 RISING NUMBER OF CLINICAL RESEARCH ENTITIES PROVIDING POST-MARKETING SURVEILLANCE TO DRIVE THE SEGMENT GROWTH 94
7 CLINICAL TRIALS MARKET, BY SERVICE TYPE 97
7.1 INTRODUCTION 98
7.2 PROTOCOL DESIGNING 99
7.2.1 PROTOCOL DESIGNING SERVICES SERVE AS AN EFFECTIVE STRATEGY TO ENSURE RAPID & EFFECTIVE PLANNING FOR CLINICAL TRIAL STUDIES 99
7.3 SITE IDENTIFICATION 101
7.3.1 NEW DIGITAL TECHNOLOGIES THAT ENABLE DATA VARIABILITY ENHANCES SITE IDENTIFICATION SERVICE EFFICACY 101
7.4 PATIENT RECRUITMENT 103
7.4.1 GROWING REQUIREMENT TO WORK WITH A PATIENT-CENTRIC CLINICAL TRIAL COMPANY SUPPORTS THE GROWTH OF THIS SEGMENT 103
7.5 LABORATORY SERVICES 105
7.5.1 INCREASING IMPORTANCE OF LABORATORY SERVICES TO ENSURE REGULATORY COMPLIANCE PROPELS THE GROWTH OF THIS SEGMENT 105
7.5.2 ANALYTICAL TESTING SERVICES 107
- 7.5.2.1 Increasing demand for analytical testing for drug development to drive the growth of this segment 107
7.6 BIOANALYTICAL TESTING SERVICES 109
7.6.1 HIGH DEMAND FOR BIOANALYTICAL TESTING DUE TO THE GROWING USE OF MACROMOLECULES AND BIOSIMILARS TO DRIVE THE GROWTH OF THIS SEGMENT 109
7.6.2 CELL-BASED ASSAYS 111
- 7.6.2.1 Increasing number of service providers offering customized cell-based assay testing services to drive the growth of this segment 111
7.6.3 VIROLOGY TESTING 113
- 7.6.3.1 Higher uptake of in vitro virology assays in the development of antiviral pharmaceuticals to drive the growth of this segment 113
7.6.4 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES 115
- 7.6.4.1 Rising importance of studies to determine pharmacokinetic behavior of drug candidates to drive the growth of this segment 115
7.6.5 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION 117
- 7.6.5.1 Increasing preference of biopharmaceutical companies to outsource method validation services for clinical trials to drive this segment 117
7.6.6 SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES 119
- 7.6.6.1 High demand for immunogenicity and neutralizing antibody assays in biosimilar development to propel market growth 119
7.6.7 BIOMARKER TESTING SERVICES 121
- 7.6.7.1 Growing emphasis on biomarker testing to develop personalized medicines and companion diagnostics to augment segment growth 121
7.6.8 OTHER BIOANALYTICAL TESTING SERVICES 122
7.7 CLINICAL TRIAL DATA MANAGEMENT SERVICES 124
7.7.1 DATA MANAGEMENT SERVICES SEGMENT IS EXPECTED TO RECORD
7.8 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES 127
7.8.1 ADVANCED DATA ANALYTICS INCORPORATED IN CLINICAL TRIAL SUPPLY MANAGEMENT IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT 127
7.9 DECENTRALIZED CLINICAL TRIAL SERVICES 128
7.9.1 THE SARS-COV-2 OUTBREAK HAS SIGNIFICANTLY CATALYZED THE DEMAND FOR DECENTRALIZED CLINICAL TRIALS 128
7.10 MEDICAL DEVICE TESTING SERVICES 130
7.10.1 INCREASING R&D FOR THE DEVELOPMENT OF ADVANCED MEDICAL DEVICES TO DRIVE THE GROWTH OF THIS MARKET 130
7.11 OTHER CLINICAL TRIAL SERVICES 132
7.11.1 OTHER CLINICAL TRIAL SERVICES SEGMENT INCLUDES CONSULTING SERVICES, MEDICAL WRITING SERVICES, AND PHARMACOGENOMICS TESTING SERVICES 132
8 CLINICAL TRIALS MARKET, BY THERAPY AREA 135
8.1 INTRODUCTION 136
8.2 ONCOLOGY 136
8.2.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH 136
8.3 INFECTIOUS DISEASES 140
8.3.1 INFECTIOUS DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD 140
8.4 NEUROLOGY 142
8.4.1 INCREASING INVESTMENTS IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH 142
8.5 IMMUNOLOGY 145
8.5.1 GROWING PIPELINE OF IMMUNOLOGICAL DRUGS HAS RESULTED IN INCREASING OUTSOURCING ACTIVITIES 145
8.6 CARDIOLOGY 147
8.6.1 HIGH MORTALITY RATES ARE DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS 147
8.7 GENETIC DISEASES 149
8.7.1 PROMISING DRUGS IN PIPELINE FOR RARE DISEASES TO SUPPORT MARKET GROWTH 149
8.8 WOMEN’S HEALTH 151
8.8.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO DRIVE MARKET GROWTH 151
8.9 OTHER THERAPY AREAS 153
9 CLINICAL TRIALS MARKET, BY APPLICATION 156
9.1 INTRODUCTION 157
9.2 SMALL MOLECULE 157
9.2.1 INCREASING INVESTMENTS BY VIRTUAL AND SMALLER COMPANIES TO DRIVE SMALL MOLECULE DEVELOPMENT PROJECTS SUPPORTS
9.3 VACCINES 160
9.3.1 OUTBREAK OF THE COVID-19 PANDEMIC IS EXPECTED TO EMERGE AS A MARKET DISRUPTOR, IMPOSING LONG-TERM POSITIVE EFFECTS ON
9.4 CELL & GENE THERAPY 162
9.4.1 THE RISING TREND OF OUTSOURCING SERVICES AND THE ONGOING EFFORTS OF SERVICE PROVIDERS TO EXPAND THEIR RESPECTIVE OFFERINGS IS DRIVING THE CLINICAL DEVELOPMENT PIPELINE FOR CELL & GENE THERAPY 162
9.5 OTHER APPLICATIONS 166
9.5.1 INCREASE IN R&D FOR THE DEVELOPMENT OF HORMONES AND BLOOD COMPONENTS SUPPORTS MARKET GROWTH 166
10 CLINICAL TRIALS MARKET, BY REGION 168
10.1 INTRODUCTION 169
10.2 NORTH AMERICA 169
10.2.1 US 173
- 10.2.1.1 Robust clinical research activities to become a key factor supporting the US market growth 173
10.2.2 CANADA 176
- 10.2.2.1 Increasing number of clinical trials in Canada to support market growth 176
10.3 EUROPE 179
10.3.1 GERMANY 182
- 10.3.1.1 Government support and flexible labor laws have made Germany a favorable location for clinical trials 182
10.3.2 UK 185
- 10.3.2.1 Investments by pharmaceutical sponsors in the UK for drug discovery services to support market growth 185
10.3.3 FRANCE 188
- 10.3.3.1 High number of oncology clinical trials in France is expected to drive market growth in France 188
10.3.4 ITALY 191
- 10.3.4.1 Low drug approval times along with the growing number of clinical trials in Italy to drive market growth 191
10.3.5 SPAIN 194
- 10.3.5.1 Rising R&D expenditure to boost market growth for clinical trials
10.3.6 REST OF EUROPE (ROE) 198
10.4 ASIA PACIFIC (APAC) 201
10.4.1 CHINA 205
- 10.4.1.1 China dominates the clinical trials services market owing to a robust pharmaceutical industry and presence of prominent clinical trial service providers 205
10.4.2 JAPAN 208
- 10.4.2.1 Strong focus on R&D activities in Japan is expected to drive market growth 208
10.4.3 INDIA 211
- 10.4.3.1 Growing pharmaceutical industry in India to drive the market growth for clinical trails 211
10.4.4 REST OF ASIA PACIFIC 214
10.5 LATIN AMERICA 217
10.5.1 GROWING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE THE MARKET
10.6 MIDDLE EAST & AFRICA 220
10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE THE MARKET GROWTH IN MIDDLE EAST & AFRICA 220
11 COMPETITIVE LANDSCAPE 224
11.1 INTRODUCTION 224
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 224
11.3 MARKET SHARE ANALYSIS 226
11.4 COMPANY EVALUATION QUADRANT 228
11.4.1 STARS 228
11.4.2 EMERGING LEADERS 228
11.4.3 PERVASIVE PLAYERS 228
11.4.4 PARTICIPANTS 228
11.5 COMPETITIVE BENCHMARKING 230
11.5.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES) 230
11.5.2 COMPANY REGIONAL FOOTPRINT (20 COMPANIES) 231
11.6 COMPETITIVE SCENARIO AND TRENDS 232
11.6.1 SERVICES LAUNCHES 232
11.6.2 DEALS 233
11.6.3 OTHER DEVELOPMENTS 234
12 COMPANY PROFILES 235
12.1 KEY COMPANIES 235
12.1.1 IQVIA 235
12.1.2 LABCORP DRUG DEVELOPMENT (COVANCE) 240
12.1.3 SYNEOS HEALTH INC. 246
12.1.4 WUXI APPTEC 252
12.1.5 CHARLES RIVER LABORATORIES 259
12.1.6 PAREXEL INTERNATIONAL 265
12.1.7 PRA HEALTH SCIENCES 271
12.1.8 PPD INC 275
12.1.9 ICON PLC 281
12.1.10 MEDPACE HOLDINGS INC 287
12.1.11 ACM GLOBAL LABORATORIES 289
12.1.12 ADVANCED CLINICAL 291
12.1.13 SGS 293
12.1.14 FRONTAGE HOLDINGS CORPORATION 296
12.1.15 PSI CRO AG 300
12.1.16 BIO AGILE THERAPEUTICS 301
12.2 OTHER PLAYERS 303
12.2.1 AZELIX 303
12.2.2 CTSERV 304
12.2.3 PEPGRA 304
12.2.4 AXCENT ADVANCED ANALYTICS (A3) 305
12.2.5 DOVE QUALITY SOLUTIONS 306
12.2.6 FIRMA CLINICAL RESEARCH 306
12.2.7 CELERION 307
12.2.8 NOVOTECH HEALTH HOLDINGS 308
12.2.9 GENETICIST INC. 308
12.2.10 LINICAL AMERICAS 309
13 APPENDIX 310
13.1 DISCUSSION GUIDE 310
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 313
13.3 AVAILABLE CUSTOMIZATIONS 315
13.4 RELATED REPORT 316
13.5 AUTHOR DETAILS 317
2017 VS. 2019 208
2021 VS. 2026 (USD BILLION) 62
TABLE 1 CLINICAL TRIALS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES TABLE 2 LIST OF BIOLOGICS APPROVED BY US FDA, 2020 TABLE 3 CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES ANALYSIS TABLE 4 SUPPLY CHAIN ECOSYSTEM TABLE 5 CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 6 EXAMPLES OF PHASE I STUDY OF DRUGS TABLE 7 PHASE I CLINICAL TRIALS MARKET, BY REGION, 2019-2026 (USD BILLION) TABLE 8 NORTH AMERICA: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY TABLE 9 EUROPE: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY TABLE 10 ASIA PACIFIC: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY TABLE 11 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES TABLE 12 PHASE II CLINICAL TRIALS MARKET, BY REGION, 2019-2026 (USD BILLION) TABLE 13 NORTH AMERICA: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY TABLE 14 EUROPE: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY TABLE 15 ASIA PACIFIC: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY TABLE 16 EXAMPLES OF DRUGS THAT HAVE COMPLETED THE PHASE III STUDY TABLE 17 PHASE III CLINICAL TRIALS MARKET, BY REGION, 2019-2026 (USD BILLION) TABLE 18 NORTH AMERICA: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY TABLE 19 EUROPE: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY TABLE 20 ASIA PACIFIC: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY TABLE 21 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES TABLE 22 PHASE IV CLINICAL TRIALS MARKET, BY REGION, 2019-2026 (USD BILLION) TABLE 23 NORTH AMERICA: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY TABLE 24 EUROPE: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY TABLE 25 ASIA PACIFIC: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY TABLE 26 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION) TABLE 27 PROTOCOL DESIGNING MARKET, BY REGION, 2019-2026 (USD BILLION) TABLE 28 NORTH AMERICA: PROTOCOL DESIGNING MARKET, BY COUNTRY TABLE 29 EUROPE: PROTOCOL DESIGNING MARKET, BY COUNTRY TABLE 30 ASIA PACIFIC: PROTOCOL DESIGNING MARKET, BY COUNTRY TABLE 31 SITE IDENTIFICATION MARKET, BY REGION, 2019-2026 (USD BILLION) TABLE 32 NORTH AMERICA: SITE IDENTIFICATION MARKET, BY COUNTRY TABLE 33 EUROPE: SITE IDENTIFICATION MARKET, BY COUNTRY TABLE 34 ASIA PACIFIC: SITE IDENTIFICATION MARKET, BY COUNTRY TABLE 35 SOME OF THE PATIENT RECRUITMENT SERVICE PROVIDERS TABLE 36 PATIENT RECRUITEMENT MARKET, BY REGION, 2019-2026 (USD BILLION) TABLE 37 NORTH AMERICA: PATIENT RECRUITEMENT MARKET, BY COUNTRY TABLE 38 EUROPE: PATIENT RECRUITEMENT MARKET, BY COUNTRY TABLE 39 ASIA PACIFIC: PATIENT RECRUITEMENT MARKET, BY COUNTRY TABLE 40 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS TABLE 41 LABORATORY SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION) TABLE 42 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY TABLE 43 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY TABLE 44 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY TABLE 45 ANALYTICAL TESTING SERVICES MARKET, BY REGION TABLE 46 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 47 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY TABLE 48 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY TABLE 49 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE TABLE 50 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION TABLE 51 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 52 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY TABLE 53 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 54 CELL-BASED ASSAYS MARKET, BY REGION, 2019-2026 (USD BILLION) TABLE 55 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY TABLE 56 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY TABLE 57 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY TABLE 58 VIROLOGY TESTING MARKET, BY REGION, 2019-2026 (USD BILLION) TABLE 59 NORTH AMERICA: VIROLOGY TESTING MARKET, BY COUNTRY TABLE 60 EUROPE: VIROLOGY TESTING MARKET, BY COUNTRY TABLE 61 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY COUNTRY TABLE 62 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION) TABLE 63 NORTH AMERICA: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 64 EUROPE: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 65 ASIA PACIFIC: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 66 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET TABLE 67 NORTH AMERICA: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 68 EUROPE: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 69 ASIA PACIFIC: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 70 SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET TABLE 71 NORTH AMERICA: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 72 EUROPE: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 73 ASIA PACIFIC: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 74 BIOMARKER TESTING SERVICES MARKET, BY REGION TABLE 75 NORTH AMERICA: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 76 EUROPE: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY TABLE 77 ASIA PACIFIC: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 78 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION TABLE 79 NORTH AMERICA: OTHER BIOANALYTICAL TESTING SERVICES MARKET TABLE 80 EUROPE: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 81 ASIA PACIFIC: OTHER BIOANALYTICAL TESTING SERVICES MARKET TABLE 82 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS TABLE 83 CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY REGION TABLE 84 NORTH AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 85 EUROPE: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET TABLE 86 ASIA PACIFIC: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET TABLE 87 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY REGION TABLE 88 NORTH AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 89 EUROPE: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET TABLE 90 ASIA PACIFIC: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET TABLE 91 DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY REGION TABLE 92 NORTH AMERICA: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET TABLE 93 EUROPE: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 94 ASIA PACIFIC: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET TABLE 95 MEDICAL DEVICE TESTING SERVICES MARKET, BY REGION TABLE 96 NORTH AMERICA: MEDICAL DEVICE TESTING SERVICES MARKET TABLE 97 EUROPE: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 98 ASIA PACIFIC: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 99 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION TABLE 100 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 101 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY TABLE 102 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 103 CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION) TABLE 104 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020) TABLE 105 CLINICAL TRIALS MARKET FOR ONCOLOGY, BY REGION TABLE 106 NORTH AMERICA: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 107 EUROPE: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY TABLE 108 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 109 CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY REGION TABLE 110 NORTH AMERICA: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES TABLE 111 EUROPE: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES TABLE 112 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES TABLE 113 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020) TABLE 114 CLINICAL TRIALS MARKET FOR NEUROLOGY, BY REGION TABLE 115 NORTH AMERICA: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 116 EUROPE: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY TABLE 117 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 118 CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY REGION TABLE 119 NORTH AMERICA: CLINICAL TRIALS MARKET FOR IMMUNOLOGY TABLE 120 EUROPE: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY TABLE 121 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 122 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020) TABLE 123 CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY REGION TABLE 124 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 125 EUROPE: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY TABLE 126 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 127 CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY REGION TABLE 128 NORTH AMERICA: CLINICAL TRIALS MARKET FOR GENETIC DISEASES TABLE 129 EUROPE: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 130 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR GENETIC DISEASES TABLE 131 CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY REGION TABLE 132 NORTH AMERICA: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH TABLE 133 EUROPE: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 134 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH TABLE 135 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020) TABLE 136 CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY REGION TABLE 137 NORTH AMERICA: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS TABLE 138 EUROPE: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS TABLE 139 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS TABLE 140 CLINICAL TRIAL MARKET, BY APPLICATION, 2019-2026 (USD BILLION) TABLE 141 CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY REGION TABLE 142 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 143 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 144 ASIA PACIFIC: CLINICAL TRIAL MARKET FOR SMALL MOLECULES TABLE 145 CLINICAL TRIALS MARKET FOR VACCINES, BY REGION TABLE 146 NORTH AMERICA: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 147 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 148 ASIA PACIFIC: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 149 CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY REGION TABLE 150 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 151 EUROPE: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 152 ASIA PACIFIC: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 153 CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2019-2026 (USD BILLION) TABLE 154 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 155 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 156 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD BILLION) TABLE 157 CLINICAL TRIALS MARKET, BY REGION, 2019-2026 (USD BILLION) TABLE 158 NORTH AMERICA: CLINICAL TRIALS MARKET, BY COUNTRY TABLE 159 NORTH AMERICA: CLINICAL TRIALS MARKET, BY PHASE TABLE 160 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET TABLE 161 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET TABLE 162 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET TABLE 163 NORTH AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 164 US: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 165 US: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION) TABLE 166 US: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 167 US: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 168 US: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION) TABLE 169 CANADA: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 170 CANADA: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 171 CANADA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 172 CANADA: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 173 CANADA: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 174 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY TABLE 175 EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 176 EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 177 EUROPE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 178 EUROPE: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 179 EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 180 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 181 GERMANY: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 182 GERMANY: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 183 GERMANY: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 184 GERMANY: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 185 UK: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 186 UK: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION) TABLE 187 UK: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 188 UK: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 189 UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION) TABLE 190 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 191 FRANCE: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 192 FRANCE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 193 FRANCE: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 194 FRANCE: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 195 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021) TABLE 196 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 197 ITALY: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 198 ITALY: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 199 ITALY: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 200 ITALY: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 201 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 202 SPAIN: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 203 SPAIN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 204 SPAIN: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 205 SPAIN: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 206 ROE: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 207 ROE: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 208 ROE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 209 ROE: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 210 ROE: CLINICAL TRIALS MARKET, BY MOLECULE, 2019-2026 (USD BILLION) TABLE 211 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY COUNTRY TABLE 212 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY PHASE TABLE 213 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 214 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION) TABLE 215 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 216 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 217 CHINA: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 218 CHINA: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 219 CHINA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 220 CHINA: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 221 CHINA: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 222 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA TABLE 223 JAPAN: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 224 JAPAN: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 225 JAPAN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 226 JAPAN: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 227 JAPAN: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 228 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA TABLE 229 INDIA: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 230 INDIA: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 231 INDIA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 232 INDIA: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 233 INDIA: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 234 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA TABLE 235 ROAPAC: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 236 ROAPAC: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 237 ROAPAC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 238 ROAPAC: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 239 ROAPAC: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 240 LATIN AMERICA: CLINICAL TRIALS MARKET, BY PHASE TABLE 241 LATIN AMERICA: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 242 LATIN AMERICA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION) TABLE 243 LATIN AMERICA: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 244 LATIN AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 245 MEA: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION) TABLE 246 MEA: CLINICAL TRIALS MARKET, BY SERVICE TYPE TABLE 247 MEA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES TABLE 248 MEA: CLINICAL TRIALS MARKET, BY THERAPY AREA TABLE 249 MEA: CLINICAL TRIALS MARKET, BY APPLICATION TABLE 250 CLINICAL TRIALS MARKET: SERVICE LAUNCHES TABLE 251 CLINICAL TRIALS MARKET: DEALS (JANUARY 2017-SEPTEMBER 2021) TABLE 252 CLINICAL TRIALS MARKET: EXPANSIONS (JANUARY 2017-NOVEMBER 2020) TABLE 253 IQVIA: BUSINESS OVERVIEW TABLE 254 IQVIA: SERVICE OFFERINGS TABLE 255 IQVIA: SERVICE LAUNCHES TABLE 256 IQVIA: DEALS TABLE 257 IQVIA: OTHER DEVELOPMENTS TABLE 258 LABCORP: BUSINESS OVERVIEW TABLE 259 LABCORP: SERVICE OFFERINGS TABLE 260 LABCORP: SERVICE LAUNCHES TABLE 261 LABCORP: DEALS TABLE 262 LABCORP: EXPANSIONS TABLE 263 SYNEOS HEALTH INC.: BUSINESS OVERVIEW TABLE 264 SYNEOS HEALTH INC.: SERVICE OFFERINGS TABLE 265 SYNEOS HEALTH INC: SERVICE LAUNCHES TABLE 266 SYNEOS HEALTH INC.: DEALS TABLE 267 WUXI APPTEC: BUSINESS OVERVIEW TABLE 268 WUXI APPTEC: SERVICE OFFERINGS TABLE 269 WUXI APPTEC: SERVICE LAUNCHES TABLE 270 WUXI APPTEC: DEALS TABLE 271 WUXI APPTEC: EXPANSIONS TABLE 272 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW TABLE 273 CHARLES RIVER LABORATORIES: SERVICE OFFERINGS TABLE 274 CHARLES RIVER LABORATORIES: DEALS TABLE 275 CHARLES RIVER LABORATORIES: EXPANSIONS TABLE 276 PAREXEL INTERNATIONAL: BUSINESS OVERVIEW TABLE 277 PAREXEL INTERNATIONAL: SERVICE OFFERINGS TABLE 278 PAREXEL INTERNATIONAL: SERVICE LAUNCHES TABLE 279 PAREXEL INTERNATIONAL: DEALS TABLE 280 PAREXEL INTERNATIONAL: EXPANSIONS TABLE 281 PRA HEALTH SCIENCES: BUSINESS OVERVIEW TABLE 282 PRA HEALTH SCIENCES: SERVICE OFFERINGS TABLE 283 PRA HEALTH SCIENCES: SERVICE LAUNCHES TABLE 284 PRA HEALTH SCIENCES: DEALS TABLE 285 PRA HEALTH SCIENCES: EXPANSIONS TABLE 286 PPD INC: BUSINESS OVERVIEW TABLE 287 PPD INC: SERVICE OFFERINGS TABLE 288 PPD: SERVICE LAUNCHES TABLE 289 PPD: DEALS TABLE 290 PPD: EXPANSIONS TABLE 291 ICON PLC: BUSINESS OVERVIEW TABLE 292 ICON PLC: SERVICE OFFERINGS TABLE 293 ICON PLC : SERVICE LAUNCHES TABLE 294 ICON PLC: DEALS TABLE 295 MEDPACE HOLDINGS INC: BUSINESS OVERVIEW TABLE 296 MEDPACE HOLDINGS INC: SERVICE OFFERINGS TABLE 297 MEDPACE HOLDINGS INC: DEALS TABLE 298 MEDPACE HOLDINGS INC: EXPANSION TABLE 299 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW TABLE 300 ACM GLOBAL LABORATORIES: SERVICE OFFERINGS TABLE 301 ADVANCED CLINICAL: BUSINESS OVERVIEW TABLE 302 ADVANCED CLINICAL: SERVICE OFFERINGS TABLE 303 SGS: BUSINESS OVERVIEW TABLE 304 SGS: SERVICE OFFERINGS TABLE 305 SGS: DEALS TABLE 306 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW TABLE 307 FRONTAGE HOLDINGS CORPORATION: SERVICE OFFERINGS TABLE 308 FRONTAGE HOLDINGS CORPORATION: DEALS TABLE 309 FRONTAGE HOLDINGS CORPORATION: EXPANSION TABLE 310 PSI CRO AG: BUSINESS OVERVIEW TABLE 311 PSI CRO AG: SERVICE OFFERINGS TABLE 312 PSI CRO AG: EXPANSIONS TABLE 313 BIO AGILE THERAPEUTICS: BUSINESS OVERVIEW TABLE 314 BIO AGILE THERAPEUTICS: SERVICE OFFERINGS TABLE 315 AZELIX: COMPANY OVERVIEW TABLE 316 CTSERV: COMPANY OVERVIEW TABLE 317 PEPGRA: COMPANY OVERVIEW TABLE 318 AXCENT ADVANCED ANALYTICS (A3): COMPANY OVERVIEW TABLE 319 DOVE QUALITY SOLUTIONS: COMPANY OVERVIEW TABLE 320 FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW TABLE 321 CELERION: COMPANY OVERVIEW TABLE 322 NOVOTECH HEALTH HOLDINGS: COMPANY OVERVIEW TABLE 323 GENETICIST INC.: COMPANY OVERVIEW TABLE 324 LINICAL AMERICAS: COMPANY OVERVIEW
FIGURE 1 CLINICAL TRIALS MARKET FIGURE 2 RESEARCH DESIGN FIGURE 3 CLINICAL TRIALS MARKET: BREAKDOWN OF PRIMARIES FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CLINICAL TRIALS IN THE MARKET FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020 FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020 FIGURE 7 CLINICAL TRIALS MARKET: CAGR PROJECTIONS, 2021-2026 FIGURE 8 CLINICAL TRIALS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH FIGURE 10 DATA TRIANGULATION METHODOLOGY FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS FIGURE 12 CLINICAL TRIALS MARKET, BY PHASE, 2021 VS. 2026 (USD BILLION) FIGURE 13 CLINICAL TRIALS MARKET, BY THERAPY AREA, 2021 VS. 2026 (USD BILLION) FIGURE 14 CLINICAL TRIALS MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION) FIGURE 15 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021 VS. 2026 (USD BILLION) FIGURE 16 GEOGRAPHICAL SNAPSHOT: CLINICAL TRIALS MARKET FIGURE 17 RISING INVESTMENTS IN THE PHARMACEUTICAL INDUSTRY TO DRIVE FIGURE 18 PHASE III SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CLINICAL TRIALS MARKET IN 2020 FIGURE 19 CELL-BASED ASSAY SEGMENT CONTINUES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD FIGURE 20 CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FIGURE 21 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012-2026 FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2011-2021 FIGURE 23 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000-2021) FIGURE 24 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010-2020 (USD BILLION) FIGURE 25 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001-2020) FIGURE 26 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CLINICAL TRIALS MARKET FIGURE 27 REVENUE SHIFT & NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS FIGURE 28 ECOSYSTEM ANALYSIS: CLINICAL TRIALS MARKET FIGURE 29 DRUGS IN THE PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020 FIGURE 30 CLINICAL TRIAL PLANNING & DESIGNING FIGURE 31 GLOBAL CANCER INCIDENCE, BY TYPE (2020) FIGURE 32 ONCOLOGY CLINICAL TRIALS GLOBALLY, 2010-2018 (THOUSAND) FIGURE 33 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FIGURE 34 SMALL MOLECULE PIPELINE: NEW CHEMICAL ENTITY, 2014-2019 FIGURE 35 COVID-19 VACCINE CANDIDATES IN CLINICAL DEVELOPMENT FIGURE 36 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY FIGURE 37 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY, BY PHASE (2020) FIGURE 38 NORTH AMERICA SNAPSHOT FIGURE 39 US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES FIGURE 40 CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018) FIGURE 41 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013-2017 (USD MILLION) FIGURE 42 SPAIN: PHARMACEUTICAL R&D EXPENDITURE (USD MILLION), 2011-2017 FIGURE 43 ASIA PACIFIC SNAPSHOT FIGURE 44 CLINICAL TRIALS MARKET: STRATEGIES ADOPTED FIGURE 45 CLINICAL TRIALS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020) FIGURE 46 CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX, 2020 FIGURE 47 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET FIGURE 48 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET FIGURE 49 IQVIA: COMPANY SNAPSHOT FIGURE 50 LABCORP: COMPANY SNAPSHOT FIGURE 51 SYNEOS HEALTH INC.: COMPANY SNAPSHOT FIGURE 52 WUXI APPTEC: COMPANY SNAPSHOT FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT FIGURE 54 PRA HEALTH SCIENCES: COMPANY SNAPSHOT FIGURE 55 PPD INC: COMPANY SNAPSHOT FIGURE 56 ICON PLC: COMPANY SNAPSHOT FIGURE 57 MEDPACE HOLDINGS INC: COMPANY SNAPSHOT FIGURE 58 SGS: COMPANY SNAPSHOT FIGURE 59 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT
